Scholarlink

<p>Lung cancer was frequently diagnosed at advanced stages (III/IV) and exhibited poor 5-year survival due to limited treatment efficacy. While immunotherapy and targeted therapies had advanced care, drug resistance persisted as a critical challenge. Our study revealed significant IDO1/PD-L1 co-expression in NSCLC. Tumor cells from patients treated with targeted therapy, chemotherapy, or immunotherapy (mono- or combination therapy) demonstrated elevated IDO1 expression. EGFR wild-type patients predominantly showed individual or co-positive IDO1/PD-L1 expression, whereas EGFR-mutant cases typically exhibited co-negative or single-negative profiles. Notably, PD-L1 single-positive patients achieved significantly or marginally prolonged OS compared to IDO1 single-positive, co-positive, or co-negative cohorts, with this survival benefit being most pronounced in EGFR wild-type subgroups. These results indicated that combined targeting of IDO1 with PD-L1/EGFR/KRAS pathways might represent a viable therapeutic approach for advanced NSCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Investigating the correlation between IDO1/PD-L1 expression or co-expression and EGFR/KRAS gene mutations in advanced NSCLC

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月7日

查看全文
  • Zhidong Yin,
  • Bohao Sun,
  • Lu Cheng,
  • Xi Xu,
  • Sisi Wang,
  • Shumei Wei,
  • Er Jin

摘要

Lung cancer was frequently diagnosed at advanced stages (III/IV) and exhibited poor 5-year survival due to limited treatment efficacy. While immunotherapy and targeted therapies had advanced care, drug resistance persisted as a critical challenge. Our study revealed significant IDO1/PD-L1 co-expression in NSCLC. Tumor cells from patients treated with targeted therapy, chemotherapy, or immunotherapy (mono- or combination therapy) demonstrated elevated IDO1 expression. EGFR wild-type patients predominantly showed individual or co-positive IDO1/PD-L1 expression, whereas EGFR-mutant cases typically exhibited co-negative or single-negative profiles. Notably, PD-L1 single-positive patients achieved significantly or marginally prolonged OS compared to IDO1 single-positive, co-positive, or co-negative cohorts, with this survival benefit being most pronounced in EGFR wild-type subgroups. These results indicated that combined targeting of IDO1 with PD-L1/EGFR/KRAS pathways might represent a viable therapeutic approach for advanced NSCLC.